The miRInform Pancreas was developed to diagnose and manage pancreatic ductal adenocarcinoma (PDAC) when cytology is inconclusive.
Astudy showed that miRInform pancreas test was able to resolve over 75% of the FNAs that were indeterminate by cytology, which comprised approximately 13% of the samples in the study.
The pancreas test combined with positive FNA cytology resulted in an overall accuracy of 92.5% versus 80.6% for cytology alone.
Asuragen CEO Matt Winkler said that they believe miRNAs will prove to be highly relevant for many additional cancer diagnostic applications.